Jarosław Czyż

Jagiellonian University — Poland

Biochemistry, Genetics and Molecular Biology · Life Sciences

34h-index5.0kcitations159works0.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Connexins and lens biology(17), Cancer Cells and Metastasis(13), Heat shock proteins research(12), Pluripotent Stem Cells Research(9), Multiple Myeloma Research and Treatments(9)

Publications159 total

<scp>RIPK</scp> 4 function interferes with melanoma cell adhesion and metastasis
Molecular Oncology·2026Open Access
Hydrogen Sulfide Inhibits H. pylori-Induced Gastric Fibroblast Activation: Implications for Cancer Prevention
Cells·2026Open Access
Pirtobrutinib vs bendamustine plus rituximab (BR) in patients with CLL/SLL: First results from a randomized phase III study Examining a non-covalent BTK inhibitor in untreated patients
Blood·2025· 2 citedOpen Access
Targeting Cancer with Redox Catalysis: Manganese Porphyrins and Ascorbate Synergistically Induce Selective Oxidative Stress and Necrotic Cell Death
Cancers·2025Open Access
Pirtobrutinib vs ibrutinib in treatment-naïve and relapsed/refractory CLL/SLL: Results from the first randomized phase III study comparing a non-covalent and covalent BTK inhibitor
Blood·2025Open Access
Targeting Cancer with Redox Catalysis: Manganese Porphyrins and Ascorbate Synergistically Induce Selective Oxidative Stress and Necrotic Cell Death
Preprints.org·2025Open Access
Endothelial activation during the diapedesis of cancer cells: between the kiss of death and therapeutic breakthrough
Cellular & Molecular Biology Letters·2025Open Access
SLPI controls neutrophil migration abilities and impacts neutrophil skin infiltration in experimental psoriasis
Cellular and Molecular Life Sciences·2025· 3 citedOpen Access
Oatmeal and wheat flour as the sources of thyroid peroxidase and proinflammatory enzymes modulators in the prevention of thyroid diseases
Scientific Reports·2025· 1 citedOpen Access
Monoclonal Antibodies Against Vascular Endothelial Growth Factor A (VEGF‐A) Reduce Synovitis, Bone Damage, and Osteogenesis in an SKG Mouse Model of Spondyloarthritis
Journal of Immunology Research·2025· 1 citedOpen Access
Reducing Cost of ILI Inspections by Assessing and Improving Accuracy of Past Inertial Surveys
2024
Metabolic reprogramming of poly(morpho)nuclear giant cells determines glioblastoma recovery from doxorubicin-induced stress
Journal of Translational Medicine·2024· 3 citedOpen Access
Tracking the Routes of Cancer: The Microevolution of Cancer-Associated Fibroblasts
Cancers·2023· 1 citedOpen Access
Mass Spectrometry-Based Assessment of M-Protein in Peripheral Blood during Maintenance Therapy in Multiple Myeloma (MM) in the Phase III ATLAS Trial
Blood·2023· 1 cited
Longitudinal Assessment of Minimal Residual Disease (MRD) in the ATLAS Randomized Phase 3 Trial of Post-Transplant Treatment with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide (R) Alone in Patients with Newly Diagnosed Multiple Myeloma (NDMM)
Blood·2023· 5 cited
P-397 Polyclonal immunoglobulin recovery in myeloma patients receiving maintenance after autologous hematopoietic stem cell transplantation with carfilzomib, lenalidomide and dexamethasone or lenalidomide
Clinical Lymphoma Myeloma & Leukemia·2023
Bronchial Fibroblasts from Asthmatic Patients Display Impaired Responsiveness to Direct Current Electric Fields (dcEFs)
Biomedicines·2023· 7 citedOpen Access
Oatmeal and wheat flour as the sources of thyroid peroxidase (TPO), lipoxygenase (LOX) and xanthine oxidase (XO) modulators potentially applicable in the prevention of inflammatory thyroid diseases
2023· 1 citedOpen Access
133 CAN HYDROGEN SULPHIDE (H2S) DONORS ACT AS A PROMISING DRUG TO REDUCE THE RISK OF HELICOBACTER PYLORI (HP)-INDUCED GASTRIC CARCINOGENESIS? STUDIES IN VITRO ON HP-INFECTED CANCER-ASSOCIATED FIBROBLASTS
Gastroenterology·2023
Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial
The Lancet Oncology·2023· 69 citedOpen Access
page 1 of 8Next →

Frequent Co-authors

Zbigniew Madeja(16), Marta Michalik(10), Anna M. Wobus(9), Damian Ryszawy(9), Urszula Gawlik‐Dziki(7), Michał Świeca(7), Katarzyna Wójcik‐Pszczoła(7), Przemysław Błyszczuk(6), Dariusz Dziki(6), Katarzyna Piwowarczyk(5), Maciej Siedlar(5), Barbara Baraniak(4), Paulina Koczurkiewicz(4), Dawid Wnuk(4), Milena Paw(4), Jan Walewski(4), Tadeusz Robak(4), Jessica Catapano(4), Marek Sanak(4), Tomasz Wróbel(4)